The Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing and manufacturing authorization to French pharma major Sanofi’s (Euronext: SAN) Wayrilz (rilzabrutinib), a novel oral reversible Bruton’s tyrosine kinase inhibitor (BTKi).
The drug is authorized for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who do not respond sufficiently to other treatments or in whom tolerability is considered to be problematic. Wayrilz can help address the underlying causes of the disease, through multi-immune modulation, targeting key pathways across the immune system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Tolebrutinib
https://en.wikipedia.org/wiki/Tolebrutinib
Wayrilz (rilzabrutinib)
https://en.wikipedia.org/wiki/Rilzabrutinib
